疾病部位靶向給藥系統(tǒng)一直是藥劑學(xué)研究的熱點(diǎn),，但人體內(nèi)非常復(fù)雜的環(huán)境因素明顯影響了藥物靶向治療的效果。腫瘤組織血管和生理特征的異常使得納米載體攜帶抗腫瘤藥物進(jìn)入機(jī)體后,，往往富集在腫瘤血管的周邊或腫瘤細(xì)胞的間隙然后釋放出藥物,，經(jīng)常導(dǎo)致細(xì)胞內(nèi)藥物的濃度較低，治療效果并不非常明顯,。
最近,，為解決這一瓶頸問(wèn)題，國(guó)家納米科學(xué)中心梁興杰課題組的研究人員采用具有腫瘤靶向性以及滲透性的新型短肽分子修飾于納米膠束表面,，通過(guò)與非功能化修飾的納米膠束對(duì)比實(shí)驗(yàn)發(fā)現(xiàn),，此靶向型納米載體系統(tǒng)可以有效增強(qiáng)載帶藥物對(duì)于腫瘤細(xì)胞的殺傷效果，在治療時(shí)間內(nèi)顯著增強(qiáng)了藥物在細(xì)胞內(nèi)的有效作用濃度,，活體動(dòng)物實(shí)驗(yàn)也表明,，此靶向膠束可以有效的富集于小鼠腫瘤組織，增強(qiáng)藥物在腫瘤組織內(nèi)的滲透,，且能維持較長(zhǎng)時(shí)間的血藥濃度,。該納米藥物載體合成方法簡(jiǎn)單易行，具有一定的應(yīng)用前景,。
目前,，相關(guān)研究成果已在線發(fā)表于《納米快報(bào)》（Nano Letters，DOI: 10.1021/nl400586t）上,。
該工作得到國(guó)家自然科學(xué)基金,、科技部納米重大研究計(jì)劃、中科院“百人計(jì)劃”等項(xiàng)目的支持,。(生物谷Bioon.com)
DOI: 10.1021/nl400586t
PMC:
PMID:
Functionalized Nanoscale Micelles Improve Drug Delivery for Cancer Therapy in Vitro and in Vivo
Tuo Wei , Juan Liu , Huili Ma , Qiang Cheng , Yuanyu Huang , Jing Zhao , Shuaidong Huo , Xiangdong Xue , Zicai Liang , and Xing-Jie Liang
In October 2011, we—David H. Gar?eld, MD, medical oncologist, United States; Harold Jacob Brenner, MD, FRCR,radiation oncologist, Israel; and Lucy Lu, oncology nurse,Shanghai, China—were part of a group that opened the ?rst of planned multiple outpatient cancer centers in China, offering radiation therapy, chemotherapy, and imaging, including magnetic resonance imaging (MRI), computed tomography (CT),ultrasound, and mammography. Although we had previously researched oncology in China, we were still in for a great many surprises
